Member Info for Soupdragon78

Greggs, I'm positive about the outcomes, just the reality of the RNS shows that the timescales have moved out.

The company quite clearly talks about NXP002 in terms of months. And as the odious UK government has utterly failed to act with any credibility on COVID then NXP004 will be delayed until Newcastle gets its equipment back, this is not looking like any time soon given the lack leadership in Downing Street.

Not expecting near term anything NXP002 related as the ebbs said they’ll update over the coming months. Might be lucky and get NXP004 news, depending on whether the Newcastle lab gets their staff and equipment back, but since the current incompetents in government seem keen to make the first wave of covid last longer than the rest of the world it might be a while.

FY results will be good to see how revenues from Ebers stack up and progress there which is key as in December they said they were expecting strong progress by end of financial year. Also it’ll compare against the initial Ebers statement of £1m revenues by end of 2019 calendar year.

It’s quite clearly mostly just traders coming in and out.
We have the odd days of higher volume upwards travel (such as 28 April with 22m volume and 2p rise) and then drops on numerous low volume days as traders who were hoping for continued rise sell out.

At 2.5p a top up of 200k shares will cost you 5 grand, whereas if you are confident it’s going down you could sell and buy back at no cost.

Really weird you Don’t want to save your money?

I’m saying you should average down, if you are confident it’s going to drop in price why not take advantage so you can get an extra lot of shares at no extra cost?
Topping up will cost you money, whereas selling and buying back lower won’t cost you anything.

ATrades, why not sell now, they’ll give you 4.255 for 300k right now. Then you can use the £12,700 to buy back 500k at 2.5p as you’re certain it’s going there.

That way you are 200k shares up, so when it goes back to 8p you’ll make an extra £16,000 on top of what you would have done?

Whimax, you forgot to add that some also defo think it’s going to go to 2-3p but they’ll only sell up at 8-10p.

Also it’s 2 months to the day since we last knew DT was selling, so the current sells are just market churn imho.

Scooby, the China issue isn’t in the past. The update clearly states they are actively trying to get the payment.

Lol! Aim4 is now trying to have a go at me on twitter by mistakenly targeting an innocent person, not understanding that I’m not even signed up to twitter, anyone can view what others post without being a member.

And all these twitter muppets all seem to be following the same racist hate spreading accounts such as Katie Hopkins, Trump and the like, what is it with these wierdos.

For some balance it’s important to look back at Vistagens news from November last year, hence my earlier comment that Nuformix appear to have been brought in to try and rescue AV-101.

The drug failed its phase 2 testing showing now signs of betterment over a placebo.

Subsequent to this they have found that if they combine the dosage with Probenecid they can achieve positive results.

Therefore they seem to be looking at finding a way to try and combining the two, this is wheee Nuformix come in with cocrystal tech.

Ps. The company rns states they are talking to multiple prospective partners.

Random, why would it be just a single preferred partner, different companies only cover certain regions. It’s likely that one company won’t take rights to all territories.

In the truest sense NFX has no need for PR as they are not selling a product to the public, what people are frustrated by is the IR, investor relations.
Personally, it’s about client relations, how they develop these, then news will follow.
It’s almost pointless them having a great amount of public info as it doesn’t benefit the company through sales etc.

Have to assume it’s the same person as she has been involved in the skyepharma merger and Activaero takeover alongside Chris Blackwell and Karl Keegan.

Vectura are certainly giving a helping hand to NFX.

At the bottom of the Business Update RNS was this...

Enquiries:
Nuformix plc
Dr Dan Gooding, Chief Executive
Officer
Fleur Wood
Email: fleur.wood@nuformix.com

A quick search reveals this from hVIVO Plc board. (hVIVO is part of Open Orphan ORPH)

Fleur Wood
Executive Vice President, Investor Relations and Communications
Fleur brings over 20 years’ experience in investor relations, communications and capital markets gained primarily within the UK investment banking industry and the pharmaceuticals sector. During her career, she has brought strategic IR skills to both M&A situations and to companies undergoing growth and change. Fleur’s previous role was at Vectura Group plc, a FTSE 250 company listed on the London Stock Exchange focussed on airways diseases, where she held positions as director of communications and director of investor relations. She played an integral role in the acquisition of Activaero GmbH in 2014 and the merger with Skyepharma plc in 2016.

That Fleur Wood has come into the mix.

Looks like it all hinges on Probenecid and Nuformix being brought in to try and rescue Av-101.

See page 119 of the company prospectus, it sets out the terms there